AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17702884 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, nonpharmacological interventions
Number of subjects: 167
Study 14741079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg/day for 6 days
Number of subjects: 130
Study 14741079 — intervention group
Group type: COMPARATOR
Intervention: Nimesulide 200 mg/day
Number of subjects: 130
Study 11515737 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed, multicultural messages
Number of subjects: 752
Study 11515737 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed, multicultural messages
Number of subjects: 752
Study 11515737 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed, ethnic-targeted messages
Number of subjects: 752
Study 9777717 — intervention group
Group type: COMPARATOR
Intervention: Erig PMC (40 IU kg(‐1) via intramuscular route)
Number of subjects: 98
Study 9777717 — intervention group
Group type: COMPARATOR
Intervention: PHT‐Erig (40 IU kg(‐1) via intramuscular route)
Number of subjects: 98
Study 9777717 — intervention group
Group type: COMPARATOR
Intervention: Erig PMC (40 IU kg(‐1) via intramuscular route) with PVRV
Number of subjects: 98
Study 9777717 — intervention group
Group type: COMPARATOR
Intervention: PHT‐Erig (40 IU kg(‐1) via intramuscular route) with PVRV
Number of subjects: 98
Study 7906108 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 5 micrograms/kg (Group 1)
Number of subjects: 64
Study 7906108 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 2.5 micrograms/kg (Group 2)
Number of subjects: 64
Study 7906108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing (Group 3)
Number of subjects: 64
Study 2460568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon gel (10^6 IU of leukocyte interferon/g)
Number of subjects: 89
Study 2460568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon gel with nonoxynol-9
Number of subjects: 89
Study 2460568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gel base alone)
Number of subjects: 89
Study 31595423 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg, once daily) for 12 months in RTT patients
Number of subjects: 26
Study 31595423 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg) for 30 days in healthy adults
Number of subjects: 26
Study 31595423 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (1 g green tea extract containing 50% EGCG) for 30 days in healthy adults
Number of subjects: 26
Study 31595423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 U.I.) for 30 days in healthy adults
Number of subjects: 26
Study 31595423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g) for 30 days in healthy adults
Number of subjects: 26
Study 31595423 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (325 mg) for 30 days in healthy adults
Number of subjects: 26
Study 29864295 — intervention group
Group type: EXPERIMENTAL
Intervention: Drifting bi-Maxwellians modeling of ion components
Number of subjects: 309
Study 29864295 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-wavelength instabilities
Number of subjects: 309
Study 29864295 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolved proton beam presence
Number of subjects: 309
Study 29864295 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable spectra
Number of subjects: 309
Study 29864295 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable spectra with large He^{2+} drift speeds
Number of subjects: 309
Study 28117133 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 139
Study 28117133 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 genetic polymorphisms
Number of subjects: 139
Study 26169093 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 80
Study 26169093 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 80
Study 23688751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab combined with glucocorticoids (prednisone 60, 30, 20, 10 mg/day on days 5-28)
Number of subjects: 74
Study 23688751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab combined with glucocorticoids (prednisone)
Number of subjects: 74
Study 23688751 — intervention group
Group type: COMPARATOR
Intervention: Control group (dexamethasone 40 mg/day on days 1-4, followed by rituximab 100 mg on days 7, 14, 21, 28)
Number of subjects: 74
Study 23688751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 21492145 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy participants
Number of subjects: 0
Study 21492145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad participants
Number of subjects: 0
Study 18725240 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive group (n=9)
Number of subjects: 17
Study 18725240 — intervention group
Group type: COMPARATOR
Intervention: Negative group (n=8)
Number of subjects: 17
Study 17315708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus 10 longidase injections in a dose of 3000 IU
Number of subjects: 28
Study 17315708 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 28
Study 12817526 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg alone for 10 days
Number of subjects: 8
Study 12817526 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.25 mg with Crataegus special extract WS 1442 (hawthorn) 450 mg twice daily for 21 days
Number of subjects: 8
Study 10917408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 to 3,600 mg/day)
Number of subjects: 103
Study 10917408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8672615 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (1 g/100 ml NaCl 0.9%)
Number of subjects: 117
Study 8672615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml NaCl 0.9%)
Number of subjects: 117
Study 1479527 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 6375890 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of tyrosine-adsorbed, glutaraldehyde-modified Dermatophagoides pteronyssinus antigen
Number of subjects: 51
Study 6375890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6375890 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 51
Study 6375890 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 51
Study 6375890 — intervention group
Group type: COMPARATOR
Intervention: Active treatment and placebo
Number of subjects: 51
Study 31298494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral massage for 30 minutes during labor
Number of subjects: 60
Study 31298494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 30100320 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 58
Study 30100320 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Myofascial Release (MFR)
Number of subjects: 58
Study 30100320 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SS and remote MFR
Number of subjects: 58
Study 30100320 — intervention group
Group type: COMPARATOR
Intervention: Self‐administered interventions (all groups)
Number of subjects: 58
Study 27051992 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated drink (80 mg of caffeine)
Number of subjects: 104
Study 27051992 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated drink
Number of subjects: 104
Study 25725933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25725933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC 10-mg
Number of subjects: 14
Study 25725933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC 20-mg
Number of subjects: 14
Study 25725933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC (10-mg and/or 20-mg)
Number of subjects: 14
Study 25725933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 14
Study 23593607 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV (1 mg) monotherapy
Number of subjects: 48
Study 23593607 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM+ADV combination therapy
Number of subjects: 48
Study 23593607 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV (1 mg)+ADV combination therapy
Number of subjects: 48
Study 20131569 — intervention group
Group type: EXPERIMENTAL
Intervention: Reacher
Number of subjects: 41
Study 20131569 — intervention group
Group type: COMPARATOR
Intervention: Unaided hand
Number of subjects: 41
Study 18389339 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine administered orally for 4 weeks
Number of subjects: 0
Study 18389339 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine in vitro
Number of subjects: 0
Study 18389339 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine with L-arginine
Number of subjects: 0
Study 16669729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 572
Study 16669729 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 572
Study 12786707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 41
Study 12786707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11129741 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based general exercise program
Number of subjects: 300
Study 11129741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 300
Study 9175387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical misoprostol (100 ug)
Number of subjects: 100
Study 9175387 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol (100 ug)
Number of subjects: 100
Study 8181831 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous hydroxyapatite in blocks (HA-B)
Number of subjects: 2
Study 8181831 — intervention group
Group type: COMPARATOR
Intervention: Porous hydroxyapatite in granules (HA-G)
Number of subjects: 2
Study 3083212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg qd)
Number of subjects: 47
Study 3083212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3083212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (for 3 weeks)
Number of subjects: 47
Study 3083212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in single-blind fashion)
Number of subjects: 47
Study 29572130 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered exercise therapy by physiotherapists
Number of subjects: 20
Study 26865258 — intervention group
Group type: EXPERIMENTAL
Intervention: BWL+H
Number of subjects: 201
Study 26865258 — intervention group
Group type: COMPARATOR
Intervention: BWL
Number of subjects: 201
Study 24894077 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HT) performed by a qualified therapist, 6 sessions over 3 months
Number of subjects: 260
Study 24894077 — intervention group
Group type: COMPARATOR
Intervention: Gut-directed hypnotherapy (HT) through self-exercises at home using CD, 3 months
Number of subjects: 260
Study 24894077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (individual HT and CD-based HT)
Number of subjects: 260
Study 23914827 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical care plus pelvic physiotherapy (maximum of six contacts)
Number of subjects: 0
Study 23914827 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (at least three contacts during five months)
Number of subjects: 0
Study 20178872 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT)
Number of subjects: 237
Study 20178872 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 237
Study 18231889 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture (n=125)
Number of subjects: 386
Study 18231889 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus specific stabilising exercises (n=131)
Number of subjects: 386
Study 18231889 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (n=130)
Number of subjects: 386
Study 18231889 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 386
Study 16680474 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-preserving pancreatic head resection (OPPHR)
Number of subjects: 40
Study 16680474 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 40
Study 16680474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OPPHR and PPPD
Number of subjects: 40
Study 12490815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy transurethral microwave thermotherapy
Number of subjects: 0
Study 12490815 — intervention group
Group type: COMPARATOR
Intervention: Transurethral microwave thermotherapy
Number of subjects: 0
Study 12490815 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 12490815 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 0
Study 10885549 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 10885549 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (conventional laparotomy)
Number of subjects: 0
Study 8831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium doses adjusted to achieve a serum lithium concentration of 0.8 to 1.0 mmol/liter (standard)
Number of subjects: 90
Study 8831438 — intervention group
Group type: COMPARATOR
Intervention: Lithium doses adjusted to achieve a serum lithium concentration of 0.4 to 0.6 mmol/liter (low)
Number of subjects: 90
Study 1426392 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival antibiotics and steroids
Number of subjects: 60
Study 1426392 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics and steroids
Number of subjects: 60
Study 3897156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-beam treatment (neutron/photon)
Number of subjects: 91
Study 3897156 — intervention group
Group type: COMPARATOR
Intervention: Photon radiation therapy (X ray)
Number of subjects: 91
Study 31888569 — intervention group
Group type: EXPERIMENTAL
Intervention: FANMI intervention (community-based cohort care)
Number of subjects: 160
Study 31888569 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine HIV care and individual counseling)
Number of subjects: 160
Study 29770998 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal depressive symptoms (MDS)
Number of subjects: 2934
Study 29770998 — intervention group
Group type: COMPARATOR
Intervention: Low maternal depressive symptoms (MDS)
Number of subjects: 2934
Study 27392137 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg daily
Number of subjects: 12
Study 27392137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27392137 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 12
Study 27392137 — intervention group
Group type: COMPARATOR
Intervention: Donepezil and Placebo
Number of subjects: 12
Study 23361084 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab (10 mg/kg)
Number of subjects: 42
Study 23361084 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 22584134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP <120 mmHg)
Number of subjects: 1028
Study 22584134 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP 130‐139 mmHg)
Number of subjects: 1028
Study 20333742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Number of subjects: 19
Study 20333742 — intervention group
Group type: COMPARATOR
Intervention: Local narrow-band ultraviolet B (NB-UVB)
Number of subjects: 19
Study 18501008 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised activity programme based on goal setting and progression of difficulty of activities delivered by a trained nurse during 8 home visits over 6 months
Number of subjects: 0
Study 18501008 — intervention group
Group type: COMPARATOR
Intervention: Time matched home visits to discuss social contacts and networks
Number of subjects: 0
Study 18501008 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised activity programme
Number of subjects: 0
Study 19571079 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular Metal tibial component
Number of subjects: 70
Study 19571079 — intervention group
Group type: COMPARATOR
Intervention: Cemented tibial component
Number of subjects: 70
Study 15111668 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual delayed matching‐to‐sample task (DMS48)
Number of subjects: 23
Study 15111668 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study 15111668 — intervention group
Group type: COMPARATOR
Intervention: Patients with mild AD
Number of subjects: 23
Study 15111668 — intervention group
Group type: COMPARATOR
Intervention: Patients with moderate AD
Number of subjects: 23
Study 15111668 — intervention group
Group type: COMPARATOR
Intervention: Patients with Parkinson disease (PD)
Number of subjects: 23
Study 11558965 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 7
Study 11558965 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy adults)
Number of subjects: 7
Study 15321185 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 0
Study 15321185 — intervention group
Group type: COMPARATOR
Intervention: Placebo wristbands
Number of subjects: 0
Study 8168348 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 60
Study 8168348 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin 150 mg twice daily for 7 days
Number of subjects: 60
Study 3349293 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 gastrectomy
Number of subjects: 43
Study 3349293 — intervention group
Group type: COMPARATOR
Intervention: R1 gastrectomy
Number of subjects: 43
Study 3349293 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 and R2 gastrectomy
Number of subjects: 43
Study 31490862 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 145
Study 31490862 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 145
Study 28364504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 12 mg
Number of subjects: 14
Study 28364504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27440679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mola curry (experimental group)
Number of subjects: 196
Study 27440679 — intervention group
Group type: COMPARATOR
Intervention: Rui curry with added retinyl palmitate (positive control group)
Number of subjects: 196
Study 27440679 — intervention group
Group type: COMPARATOR
Intervention: Rui curry (negative control group)
Number of subjects: 196
Study 24866121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 40
Study 22082303 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine and heparin
Number of subjects: 18
Study 22082303 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study 19708504 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I treatment with oral methyloprednisolone (MP) over 30 days starting at 16 mg/day
Number of subjects: 21
Study 19708504 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 hyperthyroid patients with no GO symptoms)
Number of subjects: 21
Study 19708504 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I treatment
Number of subjects: 21
Study 19708504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 19708504 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied group
Number of subjects: 21
Study 17536225 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment adjustment (increase or decrease)
Number of subjects: 59
Study 17536225 — intervention group
Group type: COMPARATOR
Intervention: Control group (41 matched patients, treatment unchanged)
Number of subjects: 59
Study 17536225 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (adjusted treatment)
Number of subjects: 59
Study 15601804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 31.25 mg
Number of subjects: 20
Study 15601804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg
Number of subjects: 20
Study 15601804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Number of subjects: 20
Study 15601804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg
Number of subjects: 20
Study 15601804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15601804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (all doses)
Number of subjects: 20
Study 15601804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 20
Study 11860412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g (LAC)
Number of subjects: 228
Study 11860412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg (LMC)
Number of subjects: 228
Study 11860412 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant patients treated with LAC
Number of subjects: 228
Study 11860412 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant patients treated with LMC
Number of subjects: 228
Study 10453438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (15% of energy from fat, maintenance of energy intake)
Number of subjects: 113
Study 10453438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (25% energy reduction)
Number of subjects: 113
Study 10453438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination low fat and low energy diet
Number of subjects: 113
Study 10453438 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention diet
Number of subjects: 113